Vanguard Fiduciary Trust
ADCT icon

Vanguard Fiduciary Trust’s ADC Therapeutics ADCT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.5K Sell
56,503
-32,404
-36% -$94.5K ﹤0.01% 3831
2026
Q1 		$333K Buy
+88,907
New +$351K ﹤0.01% 3352

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Fiduciary Trust's ADCT Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its ADC Therapeutics (ADCT) stake by 36% in Q2 2026, selling an estimated $94.5K and leaving 56,503 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3831.

Vanguard Fiduciary Trust first reported a position in ADCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $333K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Vanguard Fiduciary Trust held 56,503 shares of ADC Therapeutics worth $60.5K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 32,404 ADC Therapeutics shares in Q2 2026, an estimated $94.5K.
  • ADC Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3831 holding.
  • Vanguard Fiduciary Trust first reported a position in ADC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's ADC Therapeutics position peaked at $333K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.